DAC vs no-DAC
CJC-1295 Ipamorelin: DAC vs No-DAC Explained
What the Drug Affinity Complex actually is, why it stretches the half-life from minutes to days, and why the distinction changes everything downstream.
The short version
When people compare DAC and no-DAC, they are comparing two forms of just the CJC-1295 half of CJC-1295 Ipamorelin — the ipamorelin half is the same either way. "DAC" stands for Drug Affinity Complex: a small chemical tag added to the peptide that grabs onto albumin, a long-lived protein in your blood, and rides along with it for days. With that tag, CJC-1295 keeps nudging growth hormone (GH) up for roughly six to eight days from a single dose. Drop the tag and you have the "no-DAC" form, usually called Mod GRF (1-29), which gives a short, sharp GH signal lasting about thirty minutes — much closer to the body's own natural GHRH pulse. Same receptor, same basic action; wildly different duration. That one difference shapes how each form behaves and why they are not interchangeable.
What the DAC actually is
The Drug Affinity Complex is a C-terminal N-epsilon-maleimidopropionamide-lysine moiety — a reactive chemical group bolted onto the end of the peptide. After injection, it covalently bonds to the Cys34 thiol of serum albumin, the most abundant protein in blood plasma [5]. That covalent bond is the trick: instead of being filtered out or chewed up within minutes, the peptide is now attached to a protein the body keeps in circulation for weeks. In rats, this bioconjugation produced about a four-fold increase in GH area-under-the-curve over two hours versus unmodified GHRH(1-29), with albumin-bound peptide still detectable in plasma beyond 72 hours [5]. CJC-1295 also carries DPP-IV-resistant amino-acid substitutions, so it survives the enzyme that rapidly clips native GHRH [11].
What that buys you, in human data
The albumin trick translates into the multi-day profile measured in people. In healthy adults, a single subcutaneous dose of CJC-1295 (with DAC) raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for nine to eleven days; with repeated dosing, IGF-1 stayed elevated up to 28 days [1]. And the GH rise was physiologically reasonable: during continuous stimulation, the body's natural GH pulsing was preserved while trough GH rose about 7.5-fold, lifting mean GH 46% and IGF-1 45% [8]. So the DAC form is not a blunt, flat GH clamp — it raises the floor while the pulses keep coming.
No-DAC: the short, pulsatile alternative
The no-DAC form — mod grf 1-29 — simply omits the albumin-binding tag. Without it, the peptide behaves like native GHRH: a brief, pulsatile signal on the order of thirty minutes, cleared quickly by DPP-IV [11]. The appeal of the short form, in research-protocol logic, is that a brief GHRH pulse paired with a brief ipamorelin pulse more closely mimics the body's own coordinated bursts than a multi-day continuous GHRH drive does. The trade-off is obvious: frequent signals versus a single long one. Neither is established as safer or more effective in humans, because the comparison has not been run in a controlled trial — and neither CJC-1295 form is FDA-approved.
Why the distinction matters for the pairing
Here is the practical consequence for CJC-1295 Ipamorelin as a pairing. Ipamorelin is short-acting — a single GH pulse cleared within hours [2]. Pair it with no-DAC CJC-1295 and both arms are brief and roughly time-matched, echoing the synergy experiments that studied short, simultaneous pulses [3]. Pair it with DAC CJC-1295 and you have an hours-long pulse layered on a days-long continuous GHRH background — a genuinely different exposure profile that the synergy literature never tested. This is why the DAC-versus-no-DAC choice is not a footnote: it determines whether the pairing resembles the studied synergy or a much longer continuous drive whose net GH exposure is uncharacterized.